Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2022-11-08 Regulatory Filings
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2022-11-08 English
6-K
Regulatory Filings
2022-11-08 English
6-K
Regulatory Filings
2022-11-08 English
QIAGEN exceeds outlook for Q3 2022 with 18% CER sales growth in non-COVID product portfolio and raises full-year 2022 outlook
Earnings Release Classification · 100% confidence The document is a press release dated November 7, 2022, announcing QIAGEN's financial results for the third quarter (Q3 2022) and the first nine months of 2022. It explicitly states key financial metrics (Net sales, EPS), raises the full-year outlook, and includes detailed tables summarizing performance. This content structure—a summary press release detailing period results and outlook adjustments—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of the results. Q3 2022
2022-11-08 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Financial Report' for the period ended June 30, 2022. It contains comprehensive financial statements, including condensed consolidated balance sheets, statements of income, statements of comprehensive income, and statements of cash flows, along with explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2022
2022-08-31 English
Half-yearly financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by QIAGEN N.V. It explicitly contains a 'U.S. GAAP Quarterly Report for the Period Ended June 30, 2022' as Exhibit 99.1. The document includes comprehensive financial statements (Balance Sheets, Income Statements, Statements of Comprehensive Income, and Statements of Changes in Equity) for the quarterly period. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2022
2022-07-29 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.